Xin Huang

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.

A. Drilon, M. Burkard, T. Owonikoko, 2020, The New England journal of medicine.

Abstract CT127: Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi)

B. Tuch, Alan Ho, N. Shukla, 2019, Clinical Trials.

Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.

A. Drilon, Keunchil Park, Y. Ohe, 2020, The New England journal of medicine.

A new ALK inhibitor overcomes resistance to first and secondgeneration inhibitors in NSCLC

Zheng Wang, Qiyuan Li, Yan Liu, 2021 .

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

A. Drilon, Keunchil Park, B. Cho, 2021, Clinical Cancer Research.

Structural basis of AZD9291 selectivity for EGFR T790M.

D. Shaw, Y. Shan, H. Choi, 2020, Journal of medicinal chemistry.

A non‐covalent inhibitor XMU‐MP‐3 overrides ibrutinib‐resistant BtkC481S mutation in B‐cell malignancies

Xianming Deng, Si-Yang Song, C. Yun, 2019, British journal of pharmacology.

1922P Exploratory patient-reported outcomes among patients with RET-mutant medullary thyroid cancer in LIBRETTO-001: A phase I/II trial of selpercatinib (LOXO-292)

D. Tan, L. Wirth, V. Subbiah, 2020 .